Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28833794 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL26621555 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL26621558 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL28833793 | 0.91 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL8270269 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL6347477 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL16765451 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL928176 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL22227624 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL6345280 | 0.88 | GPR119 (0.48) | ALDH1A1KDM4ESMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3753934-A1 | PYRIMIDINYL DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3385263-B1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10618887-B2 | Pyrimidinyl tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-02-14 | — | — | US | disclosed |
| EP-3385263-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2858499-B1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-10-20 | — | — | US | disclosed |
| US-9394277-B2 | Pyrimidinyl tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017155-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885KDM4E 1291/4885SMN1; SMN2 3842/4885 |
| US-20230174511-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3781/4885KDM4E 1148/4885SMN1; SMN2 3720/4885 |
| US-20150158843-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885KDM4E 1291/4885SMN1; SMN2 3842/4885 |
| US-20190047986-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885KDM4E 1291/4885SMN1; SMN2 3842/4885 |
| US-20160304494-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885KDM4E 1291/4885SMN1; SMN2 3842/4885 |
| US-10618887-B2 | Pyrimidinyl tyrosine kinase inhibitors | ABL1, BTK, ABL2 | ALDH1A1 3713/4885KDM4E 1291/4885SMN1; SMN2 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.